Methicillin-resistant Staphylococcus Aureus Drugs Market Research 2023-2024 & 2029 [Yahoo! Finance]
Theravance Biopharma, Inc. - Ordinary Shares (TBPH)
Last theravance biopharma, inc. - ordinary shares earnings: 2/24 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.theravance.com/investor-relations
Company Research
Source: Yahoo! Finance
Dublin, May 30, 2024 (GLOBE NEWSWIRE) -- The "Methicillin-resistant Staphylococcus Aureus Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F" report has been added to ResearchAndMarkets.com's offering. Global Methicillin-resistant Staphylococcus Aureus Drugs Market was valued at USD 2.37 billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 5.67% through 2029 The Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market is witnessing significant growth as a response to the persistent challenges posed by antibiotic-resistant strains of Staphylococcus aureus. MRSA, a bacterium resistant to traditional antibiotics like methicillin, poses a serious threat, especially in healthcare settings. The market addresses the urgent need for effective drugs to combat MRSA infections, which can range from skin and soft tissue infections to more severe and life-threatening conditions like pneumonia a
Show less
Read more
Impact Snapshot
Event Time:
TBPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TBPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TBPH alerts
High impacting Theravance Biopharma, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
TBPH
News
- Theravance Biopharma, Inc. (NASDAQ: TBPH) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Theravance Biopharma, Inc. (NASDAQ: TBPH) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- Theravance Biopharma, Inc. (NASDAQ: TBPH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- Theravance Biopharma, Inc. (NASDAQ: TBPH) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Theravance Biopharma, Inc. (NASDAQ: TBPH) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
TBPH
Earnings
- 5/13/24 - Beat
TBPH
Sec Filings
- 6/11/24 - Form SC
- 5/22/24 - Form 4
- 5/22/24 - Form 4
- TBPH's page on the SEC website